Appointments

CN Bio has announced the appointmentofDeepakSingh as vice president of Sales and Marketing, supporting the company’s next phase of commercial development as it aims to expand international operations, product research and development and sales in key global markets.

Singh has over 30 years of commercial experience within the life sciences sphere. His appointment follows that of Dr Paul Brooks as chief executive officer in December 2022; both appointments mark part of the company’s aim to increase its international operations on both the product and service sides of the business.

Throughout his career, Singh has provided leadership to various sales and marketing teams, establishing new technologies from commercialisation through to global scale-up, as well as overseeing the expansion of some existing products and services into the drug discovery, bioproduction, research and diagnostics markets.

Prior to CN Bio, Singh was head of global commercial at PerkinElmer’s Horizon Discovery ‒ before this he was vice president of EMEA operations at Pacific Biosciences. He has previously held senior-level sales and marketing roles at Affymetrix and the Genetic Analysis Unit of Applied Biosystems. He holds a BSc in Biotechnology from the Polytechnic of Central London.

Commenting on his appointment, Singh said: “Having had extensive experience within the life science industry, I am excited by the possibilities of OOC technology, and how fast the potential of this technology is being realized. As evidenced by the recent FDA Modernization Act 2.0 legislation in the US, this is a very promising time for the technology, and I am looking forward to joining the CN Bio team to bring their cutting-edge systems to more researchers across the globe, to enable decision-making within drug discovery workflows to be made with more confidence and earlier than ever before.”

Dr Paul Brooks, CEO at CN Bio, added: “Deepak’s business and leadership experience, alongside his life science background, is of huge value to CN Bio as we drive forward with the Company’s commercial excellence strategy and build our capabilities in 2023 and beyond. Following the successful launch of our PhysioMimix Single-organ HT System in February, Deepak joins us at an exciting time and will be pivotal for the international scale-up of the marketing and distribution of this new system and our existing portfolio of MPS products and services.”